Stefan Charles Grant, M.D., J.D.
Associate Professor, Hematology & Oncology
Lung Neoplasms; Genotype; Adenocarcinoma; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung
Academic: 336-716-4464 | Department: 336-713-5172
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, Robinson M, Bitting RL, Thomas A, Alistar AT, Desnoyers RJ, Goodman M, Albright C, Porosnicu M, Vatca M, Qasem SA, DeYoung B, Kytola V, Nykter M, Chen K, Levine EA, Staren ED,.. J Hematol Oncol. 2017;10(1):100.
Mutational landscapes of smoking-related cancers in Caucasians and African Americans: precision oncology perspectives at Wake Forest Baptist Comprehensive Cancer Center. Kytola V, Topaloglu U, Miller LD, Bitting RL, Goodman MM, D Agostino RB Jr, Desnoyers RJ, Albright C, Yacoub G, Qasem SA, DeYoung B, Thorsson V, Shmulevich I, Yang M, Shcherban A, Pagni M, Liu L, Nykter M, Chen K, Hawkins GA, Grant SC,.. Theranostics. 2017;7(11):2914-2923.
Hyponatremia and hypoalbuminemia as predictive factors for response to first line treatment for metastatic non-small cell lung cancer [abstract]. Badawy AA, Khedr G, Omar A, Bae S, Arafat W, Grant S.. Ann Oncol. 2016;27(Suppl 6):118P.
Identification of independent negative prognostic factors in stage IV non-small cell lung cancer [abstract]. Badawy AA, Bae S, Grant SC.. J Clin Oncol. 2015;33(15 Suppl):e19133.
An evaluation of systemic therapy beyond second-line therapy in patients with stage IV non-small cell lung cancer [abstract]. Badawy AA, Bae S, Grant SC.. J Clin Oncol. 2015;33(15 Suppl):e19129.
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC). Allendorf DJ, Bordoni RE, Grant SC, Saleh MN, Reddy VB, Jerome ML, Dixon PM, Miley DK, Singh KP, Robert F.. Cancer Chemother Pharmacol. 2015;76(5):949-955.
Treatment beyond second line chemotherapy outside of a clinical trial is appropriate for selected NSCLC patients [abstract]. Badawy AA, Bae S, Grant SC.. J Thorac Oncol. 2015;10(9 Suppl 2):S654.
An evaluation of chemotherapy regimens in an unselected population of NSCLC patients [abstract]. Badawy AA, Bae S, Grant SC.. J Thorac Oncol. 2015;10(9 Suppl 2):S317.
Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I dose-expansion study in patients with squamous cell carcinoma of the head and neck [abstract]. Bendell J, Grant S, Janku F, Infante J, William WN, Bauer TM, Piha-Paul S, Martinez R, Wijayawardana S, Lin J, Golden L, Lin AB, Hong D.. Cancer Res. 2015;75(15 Suppl):CT240.
Making the diagnosis of cardiac tamponade in lung cancer patients [abstract]. Ghatalia P, Wang C, Grant SC.. J Thorac Oncol. 2015;10(9 Suppl 2):S537.
Robotic thoracic surgery for elderly patients with non-small cell lung cancer [abstract]. Hughes RT, Dipasquale VM, Grant SC, Lally BE, Petty WJ, Proto A, Wudel LJ.. J Thorac Oncol. 2015;10(9 Suppl 2):S561.
Nodal staging via robotic-assisted thoracic surgery for clinical stage I non-small cell lung cancer [abstract]. Dipasquale VM, Hughes RT, Grant S, Lally BE, Petty WJ, Proto A, Wudel LJ.. J Thorac Oncol. 2015;10(9 Suppl 2):S333.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.
The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.
Jesus Christ and *Doctor Grant have gave an new life.
I have always been a very independent person, but a time came when I had a depend on others. It Jesus Christ. And *Doctor Grant. #9. WOW.
When *Dr. Matsingo left I got *Dr. Grant and we established a good rapport. He is soft spoken and very caring. He approaches you with true kindness. He is indeed an asset to Baptist Hospital.
Dr. Grant is awesome !!!
Dr. Grant seemed a bit rushed on the last visit, overall he's been very helpful and professional in decsribing in detail my needs through the cancer chemo process